Previous studies have detected TP53 and KRAS mutations in patients with advanced cholangiocarcinoma who benefited from immunotherapy, whereas patients with single KRAS mutations had a poorer prognosis [34]. This evidence concerns the gene KRAS and cholangiocarcinoma.